+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

CAR T - Pipeline Insight, 2022

  • PDF Icon

    Clinical Trials

  • 665 Pages
  • February 2022
  • Region: Global
  • DelveInsight
  • ID: 5145405
The publisher’s, “CAR-T - Pipeline Insight, 2022,” report provides comprehensive insights about 120+ companies and 460+ pipeline drugs in CAR-T pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

CAR-T Understanding

CAR-T: Overview

CAR-T is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient’s blood. Then the gene for a special receptor that binds to a certain protein on the patient’s cancer cells is added to the T cells in the laboratory. The special receptor is called a chimeric antigen receptor (CAR). Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion. CAR T-cell therapy is used to treat certain blood cancers, and it is being studied in the treatment of other types of cancer. Also called chimeric antigen receptor T-cell therapy.

'CAR-T - Pipeline Insight, 2022' report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the CAR-T pipeline landscape is provided which includes the disease overview and CAR-T treatment guidelines. The assessment part of the report embraces, in depth CAR-T commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, CAR-T collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

  • The companies and academics are working to assess challenges and seek opportunities that could influence CAR-T R&D. The therapies under development are focused on novel approaches to treat/improve CAR-T.

CAR-T Emerging Drugs Chapters

This segment of the CAR-T report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

CAR-T Emerging Drugs

JWCAR029: JW Therapeutics

JWCAR029 is a CAR-T cell product targeting CD19, which is intended to treat late-stage lymphoma and leukemia (Second-line therapy or greater). The molecule is in phase-II stage of development. Initially, JWCAR029 is being studied for the treatment of B-cell malignancies focusing on relapsed and refractory DCBCL. In June 2020, the National Medical Products Administration (“NMPA”) accepted for review its NDA relating to relma-cel as a third-line treatment for DLBCL.

CT 103A: Innovent Biologics

CT103A is an innovative therapy co-developed by IASO BIO and Innovent. Previous studies indicate patients with relapsed/refractory multiple myeloma (RRMM) who received high-dose BCMA-targeting CAR-T cells may achieve better remission but have worse adverse events. Moreover, once the disease progresses again, the re-infusion of CAR-T cells is not effective. To solve this dilemma, CT103A has been developed, a lentiviral vector containing a CAR structure with a fully human scFv, CD8a hinger and transmembrane, 4-1BB co-stimulatory and CD3z activation domains. Based on strict selection and screening, utilizing a proprietary in-house optimization platform, the construct of the CT103A CAR-T is potent and persistent. According to the company’s pipeline, the drug is currently in Phase III stage of clinical trial evaluation to treat multiple myeloma.

CEA CAR T: Sorrento Therapeutics

Sorrento Therapeutics through its wholly-owned subsidiary TNK Therapeutics is developing CEA CAR T. It is a CAR T-cells targeting carcinoembryonic antigen (CEA). The drug is in phase II/III stage of development.

Descartes-11: Cartesian Therapeutics

Descartes-011 are autologous CD8+ T-cells expressing an anti-BCMA chimeric antigen receptor. Descartes-11 is currently in phase II clinical trials to treat patients with multiple myeloma in an outpatient setting.

CTL119: Novartis

CTL119 (CD19 CAR) is a humanized CD19 CAR under development by Novartis in collaboration with the University of Pennsylvania and currently is in Phase II stage for the treatment of Acute Lymphoid Leukemia. CTL119 is produced with a patient's T-cells, some of which are removed and then reprogrammed in Penn's Clinical Cell and Vaccine Production Facility with a gene transfer technique designed to demonstrate the T cells to target and kill tumor cells. The engineered cells contain an antibody-like protein known as a CAR, which is designed to bind to CD19 protein on the surface of cancerous B cells. The modified “hunter” cells are then infused back into the patient's body, where they multiply and are believed to attack the cancer cells.

TT11: Tessa Therapeutics

Tessa Therapeutics is developing TT11 (CD30-CAR-Tcells) in phase II stage of clinical development for the treatment of Relapsed/Refractory Hodgkin Lymphoma. The immunotherapy is CD30 targeted CAR-T cell therapy.

CD19-targeted CAR-T cells: Sinobioway Cell Therapy

CD19-targeted CAR T-cells is under development by Sinobioway Cell Therapy Co., Ltd. The therapeutic candidate is in Phase II stage of development for the treatment of Recurrent or Refractory Diffuse Large B-cell Lymphoma and Recurrent or Refractory Acute Non-T Lymphocyte Leukemia. The therapeutic candidate targets CD-19.

MB-CART2019.1: Miltenyi Biomedicine

MB-CART2019.1 is an autologous pLTG1497-transduced CAR T-cells. Miltenyi Biomedicine is developing MB-CART2019.1 for the treatment of Diffuse Large B Cell Lymphoma and B-cell Non Hodgkin Lymphoma. Zamtocabtagene autoleucel is a proposed International Nonproprietary Name of MB-CART2019.1.

EPCAM-targeted CAR T-cells: Sinobioway Cell Therapy

EPCAM-targeted CAR T-cells is under development by Sinobioway Cell Therapy Co., Ltd. The therapeutic candidate is in Phase II stage of development for the treatment of Liver Cancer and Stomach Cancer. The therapeutic candidate targets Epithelial Cell Adhesion Molecule (EPCAM). It acts by inducing lysis of tumor cells expressing Epithelial Cell Adhesion Molecule (EPCAM).

Further product details are provided in the report……..

CAR-T: Therapeutic Assessment

This segment of the report provides insights about the different CAR-T drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in CAR-T

There are approx. 120+ key companies which are developing the therapies for CAR-T. The companies which have their CAR-T drug candidates in the most advanced stage, i.e. Preregistration include, JW Therapeutics.


The publisher’s report covers around 460+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

Route of Administration

CAR-T pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical.
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

CAR-T: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses CAR-T therapeutic drugs key players involved in developing key drugs.

CAR-T Report Insights

  • CAR-T Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

CAR-T Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing CAR-T drugs?
  • How many CAR-T drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of CAR-T?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the CAR-T therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for CAR-T and their status?
  • What are the key designations that have been granted to the emerging drugs?

Table of Contents

IntroductionExecutive Summary
CAR-T: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics
  • Comparative Analysis

Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Late Stage Products (Preregistration)
  • Comparative Analysis

JWCAR029: JW therapeutics
  • Product Description
  • Research and Development
  • Product Development Activities
  • Drug profiles in the detailed report

Mid Stage Products (Phase II)
  • Comparative Analysis

Descartes-11: Cartesian Therapeutics
  • Product Description
  • Research and Development
  • Product Development Activities
  • Drug profiles in the detailed report

Early stage products (Phase I/II)
  • Comparative Analysis

CSG-CD19: Carsgen therapeutics
  • Product Description
  • Research and Development
  • Product Development Activities
  • Drug profiles in the detailed report

Inactive Products
  • Comparative Analysis
  • CAR-T Key Companies
  • CAR-T Key Products
  • CAR-T- Unmet Needs
  • CAR-T- Market Drivers and Barriers
  • CAR-T- Future Perspectives and Conclusion
  • CAR-T Analyst Views
  • CAR-T Key Companies
  • Appendix

List of Tables
Table 1 Total Products for CAR-T
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
List of Figures
Figure 1 Total Products for CAR-T
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Ziopharm Oncology Inc. and Intrexon
  • Yake Biotechnology
  • Xyphos Biosciences
  • Xi'An Yufan Biotechnology
  • Wuhan Sian Medical Technology
  • Wuhan Bio-Raid Biotechnology
  • Wugen
  • WindMIL Therapeutics
  • Wellington Zhaotai Therapies
  • VorBio
  • VCANBIO Cell & Gene Engineering Corporation, Ltd
  • UWELL Biopharma
  • Transgene
  • TrakCel
  • ToolGen
  • Tmunity Therapeutics
  • Timmune Biotech
  • TILT Biotherapeutics
  • Tianjin Mycure Medical Technology
  • The Beijing Pregene Science and Technology Company
  • Tessa Therapeutics Ltd.
  • TC BioPharm
  • Targazyme
  • Takeda / Noile-Immune Biotech
  • Synthekine
  • SymVivo
  • Sorrento Therapeutics
  • Sinobioway Cell Therapy Co., Ltd.
  • Shenzhen BinDeBio
  • Shanghai Unicar-Therapy Bio-medicine Technology
  • Shanghai Longyao Biotechnology
  • Shanghai GeneChem Co., Ltd.
  • Shanghai Biomed-union Biotechnology
  • Servier
  • Sensei Biotherapeutics
  • Senlang Bio
  • Sangamo
  • Sana Biotechnology
  • PTX Therapeutics
  • Protheragen
  • Pregene (ShenZhen) Biotechnology Company
  • Precision BioSciences
  • Precigen
  • Poseida Therapeutics
  • PersonGen BioTherapeutics (Suzhou) Co., Ltd.
  • Pepromene bio
  • Oxford Biomedica
  • Orgenesis
  • Oncternal Therapeutics
  • Novartis Pharmaceuticals
  • Noile-Immune Biotech
  • Nanjing KAEDI Biotech
  • Mustang Bio
  • MolMed
  • Minerva Biotechnologies
  • Miltenyi Biotec
  • Medisix Therapeutics
  • Maxcyte
  • Luminary Therapeutics
  • Liminatus Pharma
  • Kuur Therapeutics
  • Kite Pharma
  • Kiromic BioPharma
  • Kecellitics Biotech Company Ltd
  • JW Therapeutics
  • Janssen Pharmaceuticals
  • Intellia Therapeutics
  • Innovent Biologics
  • Innovative Cellular Therapeutics
  • InnoBation
  • IN8Bio
  • Immunicum
  • Immuneel
  • Immune Therapeutics
  • iCell Gene Therapeutics
  • iCarTAB BioMed
  • Hunan Zhaotai Yongren Medical Innovation
  • Humorigin
  • HRAIN Biotechnology
  • Henan Hualong Biotechnology
  • Hemalogix
  • Helocyte
  • Helix BioPharma
  • Hebei Senlang Biotechnology Inc., Ltd.
  • Guangzhou Bio-gene Technology
  • Guangdong Zhaotai InVivo Biomedicine Co. Ltd.
  • Grand Vista Biotechnology
  • Gracell Biotechnology
  • Glycotype
  • GlaxoSmithKline
  • Gilead Sciences
  • Genus oncology
  • GC Cell
  • Fundamenta Therapeutics
  • Fujifilm Holdings Corporation
  • Formula Pharmaceuticals
  • Fate Therapeutics
  • FastBack Bio
  • Exuma
  • Eutilex/Utilities
  • Eureka Therapeutics
  • Enlivex Therapeutics Ltd
  • Endocyte
  • Elpis Biopharmaceuticals
  • Curocell
  • CRISPR Therapeutics
  • Creative Biolabs
  • Cogent Biosciences
  • Chongqing Precision Biotechnology Co., Ltd.
  • Chimeric Therapeutics
  • Celyad Oncology SA
  • Cellular Biomedicine Group
  • Cellectis
  • Celgene
  • CASI Pharmaceuticals/Juventas Cell Therapy
  • Cartherics
  • Cartesian Therapeutics
  • Carsgen Therapeutics
  • CARsgen
  • Carina Biotech
  • Caribou Biosciences
  • Bristol-Myers Squibb
  • BrightPath Therapeutics
  • Bluebird Bio
  • Biosceptre
  • BioNTech
  • Bioceltech Therapeutics
  • Bioatla
  • Benitec Biopharma Limited
  • Bellicum Pharmaceuticals
  • Beijing Mario Biotech
  • Beijing Immunochina Medical Science and Technology
  • Beijing Doing Biomedical
  • Beijing Biohealthcare Biotechnology
  • Beam Therapeutics
  • Autolus Limited
  • Aurora Biopharma
  • Atreca/Xenor
  • Atossa Therapeutics
  • Atara Biotherapeutics
  • Arcellx Inc
  • Arbele Limited
  • Apceth Biopharma
  • Anti-CD19 chimeric antigen receptor T cell therapy - Avalon GloboCare; AVA-001 - Avalon GloboCare
  • Anixa Biosciences
  • Amgen/Kite Pharma
  • Allogene Therapeutics
  • Allife Medical Science and Technology
  • AgenTus Therapeutics
  • AffyImmune Therapeutics
  • Adicet Bio
  • Adagene
  • Actinium Pharmaceuticals
  • AbCLon
  • AbbVie
  • Obsidian Therapeutics
  • Beijing Biohealthcare Biotechnology